Advertisement
Advertisement
BEAM
Beam Therapeutics Inc. Common Stock
25.14
USDSponsored
-0.45
-1.77%
Mar 13, 16:00 UTC -4
Closed
After-Market
25.46
+0.33
+1.30%
BEAM Earnings Reports
Positive Surprise Ratio
BEAM beat 15 of 25 last estimates.
60%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$11.64M
/-$1.11
Implied change from Q4 25 (Revenue/ EPS)
-89.80%
/+1010.00%
Implied change from Q1 25 (Revenue/ EPS)
+55.85%
/-10.48%
Beam Therapeutics Inc. Common Stock earnings per share and revenue
On Feb 24, 2026, BEAM reported earnings of -0.10 USD per share (EPS) for Q4 25, beating the estimate of -1.01 USD, resulting in a 89.82% surprise. Revenue reached 114.11 million, compared to an expected 12.82 million, with a 790.23% difference. The market reacted with a +13.98% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -1.11 USD, with revenue projected to reach 11.64 million USD, implying an increase of 1010.00% EPS, and decrease of -89.80% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Mineralys Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.40
Surprise
+26.40%
Corvus Pharmaceuticals, Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.15
Surprise
-13.72%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.00
Actual
$0.01
Surprise
+16.28%
ADC Therapeutics SA
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.04
Surprise
+85.39%
Kamada Ltd
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.07
Actual
$0.06
Surprise
-24.15%
Allogene Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.22
Actual
-$0.17
Surprise
+22.73%
Molecular Partners AG - ADR
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.32
Surprise
+7.09%
Whitehawk Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.15
Actual
-$0.34
Surprise
-116.42%
Codexis, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.04
Actual
$0.11
Surprise
+357.01%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
FAQ
What were Beam Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Beam Therapeutics Inc. Common Stock reported EPS of -$0.10, beating estimates by 89.82%, and revenue of $114.11M, 790.23% above expectations.
How did the market react to Beam Therapeutics Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 13.98%, changed from $28.33 before the earnings release to $32.29 the day after.
When is Beam Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Beam Therapeutics Inc. Common Stock's next earnings report?
Based on 9
analysts, Beam Therapeutics Inc. Common Stock is expected to report EPS of -$1.11 and revenue of $11.64M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement